These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36377973)

  • 1. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
    Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
    Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
    Davis DD; Ohana Z; Pham HM
    J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
    Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
    Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
    J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK
    Curr Med Chem; 2023 Oct; ():. PubMed ID: 37818564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
    Wierda WG; Shah NN; Cheah CY; Lewis D; Hoffmann MS; Coombs CC; Lamanna N; Ma S; Jagadeesh D; Munir T; Wang Y; Eyre TA; Rhodes JM; McKinney M; Lech-Maranda E; Tam CS; Jurczak W; Izutsu K; Alencar AJ; Patel MR; Seymour JF; Woyach JA; Thompson PA; Abada PB; Ho C; McNeely SC; Marella N; Nguyen B; Wang C; Ruppert AS; Nair B; Liu H; Tsai DE; Roeker LE; Ghia P
    Lancet Haematol; 2024 Jul; ():. PubMed ID: 39033770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
    N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
    Owen C; Berinstein NL; Christofides A; Sehn LH
    Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
    Telaraja D; Kasamon YL; Collazo JS; Leong R; Wang K; Li P; Dahmane E; Yang Y; Earp J; Grimstein M; Rodriguez LR; Theoret MR; Gormley NJ
    Clin Cancer Res; 2024 Jan; 30(1):17-22. PubMed ID: 37624619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
    Thompson PA; Tam CS
    Blood; 2023 Jun; 141(26):3137-3142. PubMed ID: 37156004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.
    Liu Z; Liu J; Zhang T; Li L; Zhang S; Jia H; Xia Y; Shi M; Zhang J; Yue S; Chen X; Yu J
    BMC Cancer; 2021 Jun; 21(1):732. PubMed ID: 34174847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
    Gomez EB; Ebata K; Randeria HS; Rosendahl MS; Cedervall EP; Morales TH; Hanson LM; Brown NE; Gong X; Stephens J; Wu W; Lippincott I; Ku KS; Walgren RA; Abada PB; Ballard JA; Allerston CK; Brandhuber BJ
    Blood; 2023 Jul; 142(1):62-72. PubMed ID: 36796019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
    Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.
    Schultze MD; Reeves DJ
    Ann Pharmacother; 2024 Jan; ():10600280231223737. PubMed ID: 38235739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
    Weaver AN; Jimeno A
    Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma].
    Fileni C; Sarkozy C
    Bull Cancer; 2023 Oct; 110(10):988-990. PubMed ID: 37658026
    [No Abstract]   [Full Text] [Related]  

  • 20. Pirtobrutinib: First Approval.
    Keam SJ
    Drugs; 2023 Apr; 83(6):547-553. PubMed ID: 37004673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.